Vol.74 No.4 July 2026
Evaluation of the predictive performance of NeoVanco for vancomycin trough concentrations in Japanese neonates and infants
1)Department of Pharmacy, Sapporo City General Hospital, 13-1-1 Kita-11-jo-Nishi, Chuo-ku, Sapporo, Hokkaido, Japan
2)Department of Infectious Diseases, Sapporo City General Hospital
3)Department of Neonatology, Sapporo City General Hospital
Abstract
Vancomycin (VCM) requires individualized dosing to ensure safe and effective therapy. However, no dosing support software tailored for Japanese neonates and infants has been established yet. This study was aimed at evaluating the predictive performance of NeoVanco, an initial dosing support tool developed from U.S. population pharmacokinetic data, in Japanese neonates and infants.
This study included seven neonates and infants who received VCM at the Department of Neonatology at Sapporo City General Hospital between January 2020 and December 2024. The correlation between the predicted and observed trough concentrations was assessed using regression analysis.
The median postmenstrual age of the neonates was 32 weeks (29-35 weeks), the median weight was 1,504 g (1,193-1,711 g), and the median serum creatinine concentration was 0.33 mg/dL (0.19-0.93 mg/dL). A strong positive correlation was observed between predicted and observed trough concentrations (r=0.883). Bland-Altman analysis showed the mean difference between predicted and observed concentrations was 0.14 μg/mL, with all but one case falling within the 95% limits of agreement.
NeoVanco exhibited high predictive accuracy for estimating VCM concentrations in Japanese neonates and infants. Individualized dosing based on NeoVanco as an initial dosing support tool is expected to improve the achievement rate of target VCM concentrations.
Key word
vancomycin, neonate, infant, therapeutic drug monitoring, pharmacokinetics
Received
October 3, 2025
Accepted
March 11, 2026
Jpn. J. Chemother. 74 (4): 502-507, 2026
